AllAnalyst Report
logoMorningstarNovember 23, 2020

Eli Lilly and Company: Implementation of Trump's Recent Efforts to Affect Drug Pricing Seems Unlikely

Symbols
LLY
Sector(s)
Healthcare
Rating
Premium
Current Price
$198.48
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE

Analyst Profile

Damien Conover

Sector Director
Damien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.